Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-07-31
2007-07-31
Chen, Stacy B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100, C424S204100, C424S205100, C424S212100, C536S023100, C435S320100
Reexamination Certificate
active
09459062
ABSTRACT:
Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome modified to encode a chimeric glycoprotein incorporating one or more heterologous antigenic domains, fragments, or epitopes of a second, antigenically distinct HPIV. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, and, optionally against respiratory syncytial virus (RSV). Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a HPIV vector genome or antigenome combined or integrated with one or more heterologous genome segment(s) encoding one or more antigenic determinant(s) of a heterologous PIV to encode a chimeric glycoprotein. In preferred aspects of the invention, the chimeric virus is attenuated for use as a vaccine agent by additional mutations or nucleotide modifications introduced into the chimeric genome or antigenome.
REFERENCES:
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6264957 (2001-07-01), Collins et al.
patent: 0 440 219 (1991-08-01), None
patent: 0 702 085 (1996-03-01), None
patent: WO 93/14207 (1993-07-01), None
patent: WO 97/06270 (1997-02-01), None
patent: WO 97/11093 (1997-03-01), None
patent: WO 97/20468 (1997-06-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 98/43668 (1998-10-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 99/02657 (1999-01-01), None
patent: WO 99/15631 (1999-04-01), None
Baron et al., “Rescue of Rinderpest Virus from Cloned cDNA,”J. Virol.71:1265-1271, 1997.
Belshe et al., “Cold Adaptation of Parainfluenza Virus Type 3: Induction of Three Phenotypic Markers,”J. Med. Virol.10:235-42, 1982.
Blumberg et al., “Measles Virus L Protein Evidences Elements of Ancestral RNA Polymerase,”Virology164:487-497, 1988.
Buchholz et al., “Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter,”J. Virol.73:251-259, 1999.
Bukreyev, et al., “Recovery of Infectious Respiratory Syncytial Virus Expressing an Additional, Foreign Gene,”J. Virol.70:6634-41, 1996.
Bukreyev, et al., “Interferon γ Expressed by a Recombinant Respiratory Syncytial Virus Attenuates Virus Replication in Mice Without Compromissing Immunogenicity,”Proc. Nat. Acad. Sci. USA96:2367-2372, 1999.
Cadd et al., “The Sendai Paramyxiovirus Accessory C Proteins Inhibit Viral Genome Amplification in Promoter-Specific Fashion,”J. Virol.70:5067-74, 1996.
Collins, et al., “Production of Infectious Human Respiratory Syncytial Virus from Cloned cDNA Confirms an Essential Role of the Transcription Elongation Factor from the 5′ Proximal Open Reading Frame of the M2 mRNA in Gene Expression and Provides a Capability for Vaccine Development,”Proc Nat. Acad. Sci. USA92:11563-11567, 1995.
Collins et al., “Parainfluenza Viruses”, inFields Virology, B. N. Fields (Knipe et al., eds.), 3rded., vol. 1, p. 1205-1243, Lippincott-Raven Publishers, Philadelphia, 1996.
Conzelmann et al., “Rescue of Synthetic Genomic RNA Analogs of Rabies Virus by Plasmid-Encoded Proteins,”J. Virol.68:713-719, 1994.
Conzelmann, “Genetic Manipulation on Non-Segmented Negative-strand RNA Viruses,”J. Gen. Virol.77:381-389, 1996.
Curran, et al., “Sendai Virus P Gene Produces Multiple Proteins from Overlapping Open Reading Frames,”Enzyme44:244-249, 1990.
Curran, et al., “The Sendai Virus Nonstructural C Proteins Specifically Inhibit Viral mRNA Synthesis,”Virology189:647-656, 1992.
Delenda, et al., “Normal Cellular Replication of Sendai Virus Without thetrans-Frame, Nonstructural V Protein,”Virology228:55-62, 1997.
Delenda et al., “Sendai Viruses with Altered P, V, and W Protein Expression,”Virology242:327-337, 1998.
Dimock, et al., “Rescue of Synthetic Analogs of Genomic RNA and Replicative-Intermediate RNA of Human Parainfluenza Virus Type 3,”J. Virol.67: 2772-2778, 1993.
Durbin et al., “Minimum Protein Requirements for Transcription and RNA Replication of a Minigenome of Human Parainfluenza Virus Type 3 and Evaluation of the Rule of Six,”Virology234:74-83, 1997.
Durbin et al., “Recovery of Infectious Human Parainfluenza Virus Type 3 from cDNA,”Virology235:323-332, 1997.
Finke et al. “Ambisense Gene Expression for Recombinant Rabies Virus: Random Packaging of Positive- and Negative-Strand Ribonucleoprotein Complexes into Rabies Virions,”J. Virol.71:7281-7288, 1997.
Galinski et al., “Molecular Cloning and Sequence Analysis of the Human Parainfluenza 3 Virus mRNA Encoding the P and C Proteins,”Virology155:46-60, 1986.
Galinski et al., “Molecular Cloning and Sequence Analysis of the Human Parainfluenza 3 Virus Gene Encoding the L Protein,”Virology165:499-510, 1988.
Galinski et al., “RNA Editing in the Phosphoprotein Gene of the Human Parainfluenza Virus Type 3,”Virology186:543-550, 1992.
Garcin et al., “A Highly Recombinogenic System for the Recovery of Infectious Sendai Paramyxovirus from cDNA: Generation of a Novel Copy-back Nondefective Interfering Virus,”EMBO J.14:6087-6094, 1995.
Garcin et al., “A Point Mutation in the Sendai Virus Accessory C Proteins Attenuates Virulence for Mice, But Not Virus Growth in Cell Culture,”Virology238:424-431, 1997.
Grosfeld et al., “RNA Replication by Respiratory Syncytial Virus (RSV) Is Directed by the N, P, and L Proteins; Transcription Also Occurs under These Conditions but Requires RSV Superinfection for Efficient Synthesis of Full-Length mRNA,”J. Virol.69: 5677-5686, 1995.
Hall et al., “Cold-passaged Human Parainfluenza Type 3 Viruses Containtsand Non-tsMutations Leading to Attenuation in Rhesus Monkeys,”Virus Res.22:173-184, 1992.
Hasan et al., “Creation of an Infectious Recombinant Sendai Virus Expressing the Firefly Luciferase Gene from the 3' Proximal First Locus,”J. Gen. Virol.78:2813-20, 1997.
He et al., “Recovery of Infectious SV5 from Cloned DNA and Expression of a Foreign Gene,”Virology237:249-260, 1997.
Hoffman et al., “An Infectious Clone of Human Parainfluenza Virus Type 3,”J. Virol.71:4272-4277, 1997.
Itoh et al., “Isolation of an Avirulent Mutant of Sendai Virus with Two Amino Acid Mutations from a Highly Virulent Field Strain Through Adaption to LLC-MK2Cells,”J. Gen. Virol.78:3207-3215, 1997.
Jin et al., “Recombinant Human Respiratory Syncytial Virus (RSV) from cDNA and Construction of Subgroup A and B Chimeric RSV,”Virology251:206-214, 1998.
Johnson et al., “Specific Targeting to CD4+ Cells of Recombinant Vesicular Stomatitis Viruses Encoding Human Immunodeficiency Virus Envelope Proteins,”J. Virol.71:5060-5068, 1997.
Juhasz et al., “The Temperature-Sensitive (ts) Phenotype of a Cold-Passage (cp) Live Attenuated Respiratory Syncytial Virus Vaccine Candidate, Designatedcpts530, Results from a Single Amino Acid Substitution in the L Protein,”J. Virol.71:5814-5819, 1997.
Kahn et al., “Recombinant Vesicular Stomatitis Virus Expressing Respiratory Syncytial Virus (RSV) Glycoproteins: RSV Fusion Protein Can Mediate Infection and Cell Fusion,”Virology254:81-91, 1999.
Karron et al., “A Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine is Safe, Infectious, Immunogenic, and Phenotypically Stable in Infants and Children,”J. Inf. Dis.171:1107-1114, 1995.
Karron et al., “A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children,&#x
Collins Peter L.
Murphy Brian R.
Skiadopoulos Mario H.
Tao Tao
Birch & Stewart Kolasch & Birch, LLP
Chen Stacy B.
United States of America as Represented by the Dept. of Health &
LandOfFree
Construction and use of recombinant parainfluenza viruses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Construction and use of recombinant parainfluenza viruses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Construction and use of recombinant parainfluenza viruses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3749598